The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) securities between February 23, 2016 through March 18, 2016.
The complaint alleges that throughout the Class Period, the Company made material misrepresentations about the U.S. Food and Drug Administration’s approval process for its drug, KANGIO™. During a February 25, 2016 earnings call, Eagle Pharmaceuticals’ CEO stated that the Company seemed “to be on track for a March 19 approval” of its anticoagulant drug KANGIO. However, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA “cannot approve the application in its present form and requested additional information” regarding the substances used in KANGIO.
If you suffered a loss in Eagle Pharmaceuticals you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.